The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…
Genascence believes gene therapy can transform the treatment of knee osteoarthritis
[Updated on February 23 to include information on new funding from California Institute for Regenerative Medicine. ] Osteoarthritis (OA), a degenerative joint disease affecting the knee and other joints, affects hundreds of millions of people worldwide. Genascence is developing a gene therapy known as GNSC-001 for OA of the knee. A potent inhibitor of interleukin-1…
Genanscence raises $10.5 million in Series A financing
The clinical-stage biotech Genascence has closed a Series A financing led by Pacira BioSciences, generating $10.5 million. The funding round included investors Polymerase Capital, DeepWork Capital and University of Florida Research Foundation. The Palo Alto, California–based company is focused on treating musculoskeletal diseases with gene therapy. The company plans on using the funding for continued…